Last reviewed · How we verify
Insulin aspart (NovoRapid®)
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin aspart (NovoRapid®) |
|---|---|
| Also known as | NovoRapid (Novo-Nordisk) |
| Sponsor | Novo Nordisk A/S |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin aspart is a genetically engineered insulin analog with a rapid onset of action (10–20 minutes) and short duration (3–5 hours). It mimics the body's natural insulin response to meals by binding to insulin receptors, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. Its rapid kinetics make it suitable for mealtime insulin therapy in both type 1 and type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (PHASE1)
- Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (PHASE3)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
- Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin aspart (NovoRapid®) CI brief — competitive landscape report
- Insulin aspart (NovoRapid®) updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI